Lovenox
Company: Rhone Poulenc Rorer
Approval Status: Approved February 1998
Treatment for: prevention of blood clots following hip-replacement surgery
Areas: Hematology; Musculoskeletal
Possible similar drugs: Lovenox; Lovenox
| General Information | Clinical Results | Side Effects | Mechanism of Action |
General Information
Lovenox (enoxaparin sodium) Injection has been approved for the extended prevention of deep-vein thrombosis (DVT) following hip replacement surgery. It was previously approved for use in a hospital setting, and is the first low-molecular-weight heparin to be approved for once a day at home use.
Clinical Results
In clinical studies, patients discharged for the hospital without signs of venous thromboembolic disease received either a three-week regimen of Lovenox, or placebo. Results demonstrated that the incidence of DVT during the three-week period was significantly lower in the Lovenox patients, 7% compared to 20% for placebo.
Side Effects
Nine percent of patients reported an incidence of injection-site hematoma (bruising).
Mechanism of Action
Lovenox (enoxaparin sodium) is an antithrombotic agent known as a low-molecular-weight heparin.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
